The University of Texas MD Anderson Cancer Center was awarded a $2,351,546 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on September 1, 2024, supports research to elucidate the epigenetic mechanisms and potential therapeutic targeting during response to BRAF inhibitor and anti-EGFR therapy in BRAF-mutant colorectal cancers. The research aims to improve understanding of treatment resistance and develop more effective targeted therapies for this disease. As a leading cancer research institution, MD Anderson has extensive experience conducting basic, translational, and clinical research across various cancer types, supported by both prime and subaward funding from federal agencies such as the National Institutes of Health, Department of Defense, and Department of Veterans Affairs.
Generated 3/18/25, 1:43 AM